SDP1: The regulatory aspect for ATMP
Lead: Västra Götalands läns landsting – Gothia Forum
Involved partners: Astra Zeneca AB, CombiGene AB, CellSeed Sweden AB, GE Healthcare Aktiebolag, Karolinska Universitetssjukhuset, Novartis Sverige Aktiebolag, Region Skåne, Region Örebro län, VeriGraft AB.
SDP1 aims to provide regulatory guidance around ATMPs. The group has produced a web-based regulatory guide for ATMPs: a generic process guide from the pre-clinical to clinical development phase, which is available here. The project also arranges educational activities together with Vävnadsrådets VOG cell and formulates templates for IMPD, IB, and study protocol for ATMP together with a checklist “GMP for ATMP”. Templates will be available for partners of CAMP and Swelife ATMP through partner login at this web page.
Examples of tasks and actions:
* Linking together CAMP, Swelife-ATMP and Vävnadsrådets VOG cell in terms of regulatory issues on a national level.
* Web-based regulatory guide for ATMP.
* Check lists and templates for IMPD, IB and study protocol.
* Educational program together with Vävnadsrådets VOG cell.
* Mapping of hospital pharmacy functions for ATMP and other relevant systems/functions.
Interview with project leader
Hi Ann Novotny!
What is the need your project addresses?
The need for knowledge and support about the regulatory aspects within ATMP, the need for overview of systems and visible channels in which you can get contact and support.
What is your approach to meet the need?
Listen to researchers, small and big companies and people working in the hospitals. We then try to collect relevant information and know-how on a national level and transfer it into templates, guides and education that is accessible. Everyone have their own list of things they are struggling with; each product or project is unique in some aspect. Our project group hopes to satisfy some of the items and is open for contact and input from anyone!
How will this improve Sweden´s capabilities within ATMPs?
We aim to increase the competence around ATMP development and regulations, creating accessible knowledge and a visible network. A competent network which is easy to contact will improve Sweden´s capability to support developers that want to bring ATMPs to clinic and to market.
For more information please contact Ann Novotny